Impact of body mass index on survival and serious adverse events in advanced non-small cell lung cancer treated with bevacizumab: a meta-analysis of randomized clinical trials

CONCLUSION: In this analysis of clinical trial data, obesity was not associated with worse survival versus non-obese individuals in advanced NSCLC. In addition, serious adverse events were similar between patients with and without obesity.PMID:33685311 | DOI:10.1080/03007995.2021.1900091

Source: Current Medical Research and Opinion - March 9, 2021 Category: Research Authors: Soham Shukla Zachary Babcock Laura Pizzi Luigi Brunetti Source Type: research